IQVIA Holdings Inc. $IQV Stake Raised by Handelsbanken Fonder AB

Handelsbanken Fonder AB grew its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 95.9% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 258,543 shares of the medical research company’s stock after purchasing an additional 126,554 shares during the quarter. Handelsbanken Fonder AB’s holdings in IQVIA were worth $58,278,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in IQV. Brighton Jones LLC raised its holdings in shares of IQVIA by 244.4% during the fourth quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock valued at $703,000 after buying an additional 2,537 shares during the last quarter. Empowered Funds LLC raised its holdings in shares of IQVIA by 102.1% during the first quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock valued at $1,715,000 after buying an additional 4,915 shares during the last quarter. Sivia Capital Partners LLC bought a new stake in shares of IQVIA during the second quarter valued at approximately $514,000. First Trust Advisors LP raised its holdings in shares of IQVIA by 14.8% during the second quarter. First Trust Advisors LP now owns 92,015 shares of the medical research company’s stock valued at $14,501,000 after buying an additional 11,845 shares during the last quarter. Finally, NewEdge Advisors LLC raised its holdings in shares of IQVIA by 5.4% during the second quarter. NewEdge Advisors LLC now owns 22,731 shares of the medical research company’s stock valued at $3,582,000 after buying an additional 1,155 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

IQV has been the topic of several recent analyst reports. Royal Bank Of Canada initiated coverage on IQVIA in a report on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 target price on the stock. Truist Financial dropped their target price on IQVIA from $290.00 to $245.00 and set a “buy” rating on the stock in a report on Thursday, February 19th. Jefferies Financial Group dropped their target price on IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a report on Friday, February 6th. Stifel Nicolaus dropped their target price on IQVIA from $273.00 to $220.00 and set a “buy” rating on the stock in a report on Friday, February 6th. Finally, Morgan Stanley set a $225.00 target price on IQVIA in a report on Thursday, May 7th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, IQVIA has a consensus rating of “Buy” and a consensus price target of $225.69.

IQVIA Price Performance

NYSE IQV opened at $172.86 on Tuesday. The stock has a market capitalization of $28.85 billion, a P/E ratio of 21.42, a P/E/G ratio of 1.62 and a beta of 1.18. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $247.04. The business’s fifty day moving average is $170.03 and its two-hundred day moving average is $198.74. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.75 and a current ratio of 0.75.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.83 by $0.07. The company had revenue of $4.15 billion for the quarter, compared to analysts’ expectations of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The firm’s revenue was up 8.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.70 earnings per share. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, research analysts forecast that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA declared that its board has initiated a stock buyback plan on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to reacquire up to 6.8% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company’s board believes its shares are undervalued.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.